Publications
2023
- Accidents vasculaires cérébraux suivant l’administration d’un vaccin contre la COVID-19
- Zona survenu à la suite de la vaccination contre la COVID-19 au Québec
- Paralysie de Bell survenue à la suite de la vaccination contre la COVID-19 au Québec
- Manifestations cliniques indésirables à la suite de la vaccination de base contre la COVID-19 déclarées au système de surveillance passive du Québec
- Surveillance active de la sécurité des trois premières doses de vaccin contre la COVID-19 au Québec
- Administration of COVID-19 booster doses: Recommendations for winter and spring 2023
- Administration de doses de rappel du vaccin contre la COVID-19 : recommandations pour l’hiver et le printemps 2023
2022
- Administration d’une dose de vaccin bivalent aux personnes vaccinées avec le vaccin monovalent contre la COVID-19 depuis le 15 août 2022
- Vaccination contre l’influenza et la COVID-19 à l’automne 2022
- Stratégie vaccinale contre la COVID-19 à préconiser au Québec en 2022 et pertinence d’une 2e dose de rappel pour certains groupes vulnérables
- Administration des doses subséquentes d’un vaccin contre la COVID-19 chez les personnes ayant développé une péricardite ou une myocardite
- Enquête épidémiologique sur les travailleurs de la santé atteints par la COVID-19
- Vaccination contre l’hépatite virale A suite à une éclosion à Nunavik
Publications
2023
- Pre-Omicron seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and teenagers in Montreal, Canada
- Humoral Responses against BQ.1.1 Elicited after Breakthrough Infection and SARS-CoV-2 mRNA Vaccination
- BNT162b2 effectiveness against Delta and Omicron variants of SARS-CoV-2 in adolescents aged 12-17 years, by dosing interval and duration
2022
- Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, Canada
- A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses
- Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study
- Influenza vaccine effectiveness against A(H3N2) during the delayed 2021/22 epidemic in Canada
- Risk and protective factors for SARS-CoV-2 infection among healthcare workers: a test-negative case-control study in Quebec, Canada
- Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety (CANVAS) network cohort study
- Effectiveness of COVID-19 vaccines against hospitalization and death in Canada: A multiprovincial test-negative design study
- Time trends in social contacts before and during the COVID-19 pandemic: the CONNECT study
- Time trends in social contacts of individuals according to comorbidity and vaccination status, before and during the COVID-19 pandemic
- Impact of the first vaccine dose on COVID-19 and its complications in long-term care facilities and private residences for seniors in Québec, Canada
- Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada